SCHEMBL13222018

SCHEMBL13222018

CN(NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C1CCCCC1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O

nearest known ligand 0.68

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 10/20 0.68
KISS1R Q969F8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13222021 0.88 GHSR (0.71) GHSR
SCHEMBL13222008 0.88 GHSR (0.73) GHSR
SCHEMBL19133148 0.87 GHSR (0.70) GHSR
SCHEMBL13222001 0.87 GHSR (0.82) GHSR
SCHEMBL13222010 0.87 GHSR (0.70) GHSR
SCHEMBL13222004 0.86 GHSR (0.76) GHSR
SCHEMBL13222005 0.86 GHSR (0.72) GHSR
SCHEMBL19133158 0.85 GHSR (0.69) GHSR
SCHEMBL19133150 0.85 GHSR (0.67) GHSR
SCHEMBL19088212 0.84 KISS1R (0.65) KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708370-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2017-07-18 US disclosed
US-20150329591-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) 2015-11-19 US disclosed
US-9115171-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2015-08-25 US disclosed
US-20130203686-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS INSERM (FR) 2013-08-08 US disclosed
US-8435954-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2013-05-07 US disclosed
US-8435954-B2 Azapeptides as CD36 binding compounds VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) 2013-05-07 US disclosed
US-20100210566-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2010-08-19 US disclosed
US-20100210566-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2010-08-19 US disclosed
WO-2008154738-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329591-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS MSR1, ASGR1, LDLR GHSR 398/4885KISS1R 737/4885
US-20130203686-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS MSR1, ASGR1, SCARB1 GHSR 358/4885KISS1R 702/4885
US-20100210566-A1 AZAPEPTIDES AS CD36 BINDING COMPOUNDS GHRHR, GHSR, GNRHR GHSR 2/4885KISS1R 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.